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Conclusion: Guidelines for regional LN did not significantly 
improve the consistency of contouring among ROs. The J-ROs 
were the most accurate in contouring according to AIRO 
guidelines and showed the highest level of homogeneity, 
while the S-ROs followed the guidelines to a lesser extent, 
probably because of higher self-confidence. 
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Purpose or Objective: Optimal local treatment for young 
women with early-stage breast cancer remains controversial 
because of the lack of knowledge as to whether local 
recurrence (LR) can be the site of metastatic disease. The 
aim was to describe the age depending LR pattern as a 
function of time (0-20 years) and local treatment, given as 
either Breast conserving therapy (BCT) or mastectomy alone. 
Furthermore to test, if LR was associated with an excess risk 
of distant metastasis (DM) and translate into a higher 
mortality after BCT. 
 
Material and Methods: 1077 Danish patients were enrolled in 
this population-based cohort study. The patients were 
diagnosed in the period from 1989 to 1998, classified as low-
risk (lymph-node negative, tumor size <5 cm), treated with 
mastectomy (N= 712) or BCT (N=364) and received no 
systemic treatment. The cohort included all Danish low-risk 
patients below 41 years (N = 305) and patients from one part 
of Denmark. Patient identification, treatment, and 20-year 
recurrence data were ascertained from the DBCG. 
 
 
Results: After 20 years the cum incidence of LR was 18 % 
after BCT (N=66) and 6.7% after mastectomy (N=55). The LR 
pattern of failure was different depending on age: young ( ≤45 
year) vs. old (<45 year) and treatment: BCT vs. mastectomy. 
The older mastectomy patients developed only very early LR 
(< 5 year), young mastectomy patients developed early LR (0-
10 year), and BCTpatients despite age developed LR 
throughout the 20-year period (Fig 1). Among young patients, 
the BCT group had a higher risk of LR after 20 years 
compared to the mastectomy, RD = 13% (4.8-20), and LR was 
a prognostic marker for DM, HR =2.0 (1.3-3.1). The 20-year 
mortality among the young patients was significantly higher 
after BCT compared to mastectomy: Breast cancer death, HR 
=1.6 (1.0-2.5) and Death, HR =1.7 (1.1-2.6). Among the older 
patients, LR was not a prognostic marker for DM after 20 
years, HR: 0.9 (0.3-2.2), and local treatment was not 
associated with Breast cancer death, HR =0.8 (0.5-1.2). 
 
 
Conclusion: In the group of patients treated with 
mastectomy all LR occured within the first 10 years. In 
contrast, BCT patients developed LR throughout the period 
and had a significantly higher cumulative incidence of LR at 
20 years. Within the young patients LR was associated with 
DM, and BCT was associated with a significantly higher 
mortality. Among older patients LR was not a prognostic 
marker for DM and there was no difference in Breast cancer 
mortality between the two treatment groups. 
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Purpose or Objective: To report an analysis of treatment 
outcomes and toxicity of a cohort of patients re- irradiated 
after a second breast conserving surgery or no further 
surgery. 
 
Material and Methods: Between 11/05 and 10/15, 32 women 
were re- irradiated with 50- 60 Gy for locally recurrent breast 
cancer. The first RT course included postoperative 
radiotherapy with a total dose of 50 Gy in 25 or 50,4Gy in 28 
fractions followed by a boost dose to the tumor bed 
according to risk factors in 81.3%. In 18.7% supraclavicular 
nodes were treated with 50Gy.The median age at first 
diagnosis was 53.3 years (range 36- 69.7). 78.1% of the 
women were postmenopausal. 81.25% of the tumors were 
pathologically classified as T1, 12.5% as T2 and 6.25% as 
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ductal carcinomas in situ. Axillary lymph node involvement 
was seen in 34.3%. Most of the tumors were estrogen positive 
(68.75%) and progesterone positive (65.6%). A systemic 
therapy was given in 81.25% of the patients. After second 
breast conserving therapy or no surgery re- RT was given to 
the involved quadrant using external- beam ports (electrons 
or photons) with doses of 50-60Gy in 2Gy per fraction. The 
median age at local relapse was 65.8 years. A second breast 
conserving therapy was performed in 90.7% of the women, 
9.3% had no surgery and were re-irradiated to a dose of 
60Gy. A systemic therapy was given in 84.3%.Survival and 
local control were calculated by the Kaplan-Meier actuarial 
method. 
 
Results: A total of 32 patients were retrospectively analyzed. 
The median follow up of survivors was 181 months from first 
diagnosis and 33 month from second RT. At the time of 
analysis 4 patients had died. The median time between first 
and second RT was 9.9 years (range 1.8- 20.3). Fifteen years 
after first diagnosis 86% of the patients were still alive. Four 
women died, 3 on cancer. After second RT only one acute G2 
toxicity of the skin was reported (desquamation).Late 
toxicity was scored using the LENT- SOMA Score Criteria. 
Lymphedema (G1) of the ipsilateral arm was observed in 
3.1%, 3.1% reported on intermittent pain in the breast and 
9.3% presented with an asymptomatic breast edema. The 
highest rate of late toxicity was G2 fibrosis in 18.7%.No G3 or 
G4 toxicity was observed.  
 
Conclusion: Carefully planned re-RT of the involved breast 
quadrant is a safe alternative therapy for those women who 
did not gave their consent to the recommended mastectomy. 
No second local relapse was detected after re-RT. Acute side 
effects were low. In 18.7% of the women fibrosis G2 was 
detected. 
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Purpose or Objective: Cancer en cuirasse is a severe 
locoregional manifestation of breast cancer, usually occurring 
after a number of treatment failures. Treatment options are 
limited. One hundred and sixty-nine patients were treated 
with re-irradiation and hyperthermia (reRT+HT) from 1982 till 
2006. Response and toxicity rates as well as the locoregional 
progression free interval were determined to assess the 
palliative value of this treatment. 
 
Material and Methods: All patients had received extensive 
previous treatments, including surgery, irradiation (median 
dose 50Gy with or without boost) and systemic treatments.. 
Seventy-five percent of patients had 1-7 previous 
locoregional recurrence episodes; 68% were treated with 
systemic therapies and 27% underwent salvage surgery.  
At start of re-RT+HT the tumor area comprised > 3/4 
ipsilateral chest wall in 54% of patients. Fifty-two percent 
had areas of ulcerating tumor. Distant metastases were 
present in 45% of patients. reRT consisted typically of 8x4Gy, 
twice a week or 12x3Gy, four times a week. Superficial 
hyperthermia was applied once or twice a week using 434MHz 
Contact Flexible Microstrip Applicators (CMFA), heating the 
tumor area to 41-43˚C for one hour. 
 
Results: The treatment was well tolerated; 154 patients 
completed treatment, only 15 patients did not, due to 
disease progression in 12, toxicity in 2 and refusal in 1 
patient. Overall clinical response rate was 72% (30% CR; 42% 
PR), while only 6% showed PD. Median follow-up time was 7 
months. The 1-year progression-free-interval was 24% with a 
1-year survival rate of 36%. Acute ≥ grade 3 toxicity occurred 
in 33% of patients and consisted mostly of ulceration and 
dermatitis. The occurrence of radiation ulcera was 
significantly related to the presence of ulcerating tumor 
before the start of the reRT-HT (P=0.004, HR = 4.4). 
 
Conclusion: The combination of re-irradiation and 
hyperthermia is well tolerated and results in high response 
rates despite extensive disease and resistance to previous 
treatments. ReRT+HT is a worthwhile palliative treatment 
option for this patient group who suffer from extensive 
locoregional tumor growth and have a very poor prognosis.  
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Purpose or Objective: Stereotactic radiotherapy (SRT) of 
brain metastases results in regression of most treated 
metastases, but subsequent lesion growth may occur and is 
caused by either tumor progression or pseudo-progression, 
which is probably a radiation effect on surrounding normal 
brain tissue. It is unknown if active treatment is indicated in 
symptomatic patients, or if it is better to wait for 
spontaneous recovery. The purpose of this study is to 
describe the clinical course of brain metastasis patients 
developing pseudo-progression after SRT to improve clinical 
decision-making. 
 
Material and Methods: Follow-up MRI scans of all patients 
who received SRT of brain metastases from 2009 through 
2012 were reviewed for post SRT lesion growth. Depending on 
the volume of the metastasis, the patients had received one 
fraction of 21Gy, 18Gy, or 15Gy, or three fractions of 8Gy or 
8.5Gy. The GTV-PTV margin was 2mm. Pseudo-progression 
was considered to be the cause of this lesion growth if a 
histological diagnosis of necrosis had become available, if the 
lesion had shown subsequent regression or if two neuro-
radiologists agreed upon this diagnosis based on a review of 
the follow-up perfusion MRI scans. The clinical course of the 
patients with these pseudo-progressive lesions was 
retrospectively studied. 
 
Results: In a total of 237 treated patients we identified 37 
patients with 50 pseudo-progressive lesions. The median 
follow-up of all patients still alive was 40.7 months. The main 
clinical symptoms that were attributed to this lesion growth 
were neurologic deficits, headache and seizures in 19 (51%), 
3 (8%) and 4 (11%) patients respectively (unknown in one). 
Ten patients (27%) had no symptoms attributed to the lesion 
growth and remained asymptomatic afterwards. Of the 19 
patients with neurologic deficits one improved after 
spontaneous regression of the lesion, one improved after 
surgery and 17 did not improve. Two out of the four patients 
with seizures improved with ant-epileptic drugs (AED’s), one 
improved after surgery and one did not improve. Only one of 
the three patients with headache improved with steroids. 
Spontaneous regression of an initially pseudo-progressive 
lesion was observed in 18 patients. Twelve of these 18 
patients had symptomatic pseudo-progression, but only one 
of these 12 patients experienced neurologic improvement 
without treatment. In 6 patients their deaths were related to 
the pseudo-progressive lesion.  
 
Conclusion: Patients with an asymptomatic pseudo-
progressive lesion frequently remain asymptomatic. Patients 
with a symptomatic pseudo-progressive lesion only rarely 
recover spontaneously. Active treatment, such as surgery, 
should be considered for these patients. Therefore, 
